Compare LEGN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEGN | CORT |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 9.7B |
| IPO Year | 2020 | 2001 |
| Metric | LEGN | CORT |
|---|---|---|
| Price | $19.85 | $113.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | $61.33 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 2.0M | 1.0M |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $42.68 | $26.08 |
| Revenue Next Year | $30.52 | $26.98 |
| P/E Ratio | ★ N/A | $1,299.22 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $16.24 | $28.66 |
| 52 Week High | $37.50 | $126.38 |
| Indicator | LEGN | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 55.51 |
| Support Level | $17.01 | $76.41 |
| Resistance Level | $23.66 | $122.21 |
| Average True Range (ATR) | 1.02 | 3.86 |
| MACD | 0.18 | -1.00 |
| Stochastic Oscillator | 7.41 | 29.60 |
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.